請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33815完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳振陽 | |
| dc.contributor.author | Ping-Ting Huang | en |
| dc.contributor.author | 黃馪珽 | zh_TW |
| dc.date.accessioned | 2021-06-13T05:46:41Z | - |
| dc.date.available | 2009-08-03 | |
| dc.date.copyright | 2006-08-03 | |
| dc.date.issued | 2006 | |
| dc.date.submitted | 2006-07-12 | |
| dc.identifier.citation | 1. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell P J, Gibson T J, Hatfull G, Hudson G.S, Satchwell SC, Seguin C, Tuffnell PS and Barrell BG. (1984). DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207-211.
2. Bakin AV, Safina A, Rinehart C, Daroqui C, Darbary H and Helfman DM. (2004). A critical role of tropomyosins in TGF-beta regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol Biol Cell. 15, 4682-94. 3. Bharadwaj S and Prasad GL. (2002). Tropomyosin-1, a novel suppressor of cellular transformation is downregulated by promoter methylation in cancer cells. Cancer Lett. 183, 205-13. 4. Bharadwaj S, Thanawala R, Bon G, Falcioni R and Prasad GL. (2005). Resensitization of breast cancer cells to anoikis by Tropomyosin-1: role of Rho kinase-dependent cytoskeleton and adhesion. Oncogene. 24, 8291-303. 5. Bhattacharya B, Prasad GL, Valverius EM, Salomon DS and Cooper HL. (1990). Tropomyosins of human mammary epithelial cells: consistent defects of expression in mammary carcinoma cell lines. Cancer Res. 50, 2105-12. 6. Blanchoin L, Pollard TD and Hitchcock-DeGregori SE. (2001). Inhibition of the Arp2/3 complex-nucleated actin polymerization and branch formation by tropomyosin. Curr Biol. 11, 1300-4. 7. Boyd J, Risinger JI, Wiseman RW, Merrick BA, Selkirk JK and Barrett JC. (1995). Regulation of microfilament organization and anchorage-independent growth by tropomyosin 1. Proc Natl Acad Sci USA. 92, 11534-8. 8. Burkitt DA. (1958). A sarcoma involving the jaws in African children. Brit J Surg. 45, 218-223. 9. Burkitt DA. (1962). A children’s cancer dependent upon climatic factors. Nature 194, 232-234 10. Button E, Shapland C and Lawson D. (1995). Actin, its associated proteins and metastasis. Cell Motil Cytoskeleton. 30, 247-51. 11. Chien Y C, Chen JY, Liu MY, Yang H I, Hsu M M, Chen CJ and Yang CS. (2001). Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 345, 1877-1882. 12. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN and Golub TR. (2000). Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA. 97, 3260-5. 13. Cooper JA. (2002). Actin dynamics: tropomyosin provides stability. Curr Biol.12, R523-5. 14. Dambaugh T, Beisel C, Hummel M, King W, Fennewald S, Cheung A, Heller M, Raab-Traub N and Kieff E. (1980). Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci USA .77, 2999-3003. 15. Dawson CW, Rickinson AB and Young LS. (1990). Epstein–Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 344, 777–780. 16. Dawson CW, Tramountanis G, Eliopoulos AG and Young LS. (2003). Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem. 278, 3694-704. 17. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW and Young LS. (1999). Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem. 274, 16085-96. 18. Epstein MA, Achong BG and Barr YM. (1964a). Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1, 702-3. 19. Epstein MA and Barr YM. (1964b). Cultivation in vitro of human lymphoblasts from Burkitt’s malignant lymphoma. Lancet 1, 252-3. 20. Fahraeus R, Hu LF, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, Yadav M, Busson P, Tursz T and Kallin B. (1988). Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42, 329-38. 21. Fahraeus R, Chen W, Trivedi P, Klein G and Obrink B. (1992). Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfected human epithelial and murine adenocarcinoma cells. Int J Cancer. 52, 834-8. 22. Folgueras AR, Pendas AM, Sanchez LM and Lopez-Otin C. (2004). Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 48, 411-24. 23. Franzen B, Linder S, Uryu K, Alaiya AA, Hirano T, Kato H and Auer G. (1996). Expression of tropomyosin isoforms in benign and malignant human breast lesions. Br J Cancer. 73, 909-13. 24. Gimona M, Kazzaz JA and Helfman DM. (1996). Forced expression of tropomyosin 2 or 3 in v-Ki-ras-transformed fibroblasts results in distinct phenotypic effects. Proc Natl Acad Sci U S A. 93, 9618-23. 25. Glaser P, Ogino T, Zimmerman JJ and Rapp F. (1973) Thymidine kinase activity in Burkitt lymphoblastoid somatic cell hybrids after induction of the EB virus. Proc Soc Exp Biol Med. 142, 1059-1062. 26. Gordon AM, Homsher E and Regnier M. (2000). Regulation of contraction in striated muscle. Physiol Rev. 80, 853-924. 27. Gunning PW, Schevzov G, Kee AJ and Hardeman EC. (2005). Tropomyosin isoforms: divining rods for actin cytoskeleton function. Trends Cell Biol 15, 333-41. 28. Hashimoto Y, Shindo-Okada N, Tani M, Takeuchi K, Toma H and Yokota J. (1996) Identification of genes differentially expressed in association with metastatic potential of K-1735 murine melanoma by messenger RNA differential display. Cancer Res. 56, 5266-71. 29. Hendricks M and Weintraub H. (1984). Multiple tropomyosin polypeptides in chicken embryo fibroblasts: differential repression of transcription by Rous sarcoma virus transformation. Mol Cell Biol. 4, 1823-33. 30. Henle G and Henle W. (1966). Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol. 91, 1248-56. 31. Henle G and Henle W. (1976). Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 17, 1-7. 32. Henle G, Henle W and Diehl V. (1968). Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci U S A. 59, 94-101. 33. Horikawa T, Sheen TS, Takeshita H, Sato H, Furukawa M and Yoshizaki T. (2001) Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol. 159, 27-33. 34. Horikawa T, Yoshizaki T, Sheen TS, Lee SY and Furukawa M. (2000). Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer. 89, 715-23. 35. Hu LF, Chen F, Zhen QF, Zhang YW, Luo Y, Zheng X, Winberg G, Ernberg I and Klein G. (1995). Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur J Cancer. 31A, 658–60 36. Ishikawa R, Yamashiro S and Matsumura F. (1989). Differential modulation of actin-severing activity of gelsolin by multiple isoforms of cultured rat cell tropomyosin. Potentiation of protective ability of tropomyosins by 83-kDa nonmuscle caldesmon. J Biol Chem. 264, 7490-7. 37. Izumi KM, Kaye KM and Kieff ED. (1994). Epstein–Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation. J Virol. 68, 4369–76. 38. Janssen RA and Mier JW. (1997). Tropomyosin-2 cDNA lacking the 3' untranslated region riboregulator induces growth inhibition of v-Ki-ras-transformed fibroblasts. Mol Biol Cell. 8, 897-908. 39. Janssen RA, Veenstra KG, Jonasch P, Jonasch E and Mier JW. (1998). Ras- and Raf-induced down-modulation of non-muscle tropomyosin are MEK-independent. J Biol Chem. 273, 32182-6. 40. Jung MH, Kim SC, Jeon GA, Kim SH, Kim Y, Choi KS, Park SI, Joe MK and Kimm K. (2000). Identification of differentially expressed genes in normal and tumor human gastric tissue. Genomics. 69, 281-6. 41. Kaye KM, Izumi KM and Kieff E. (1993). Epstein–Barr virus latent membrane protein 1 is essential for B lymphocyte growth transformation. Proc Natl Acad Sci USA. 90, 9150–54. 42. Kieff E and Rickinson AB. (2001). Epstein–Barr virus and its replication. 4th ed. in Fields Virology. Vol.2 , 2511-2573. Lippincott Williams and Wilkins, Philadelphia. 43. Kilger E, Kieser A, Baumann M and Hammerschmidt W. (1998). Epstein–Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which stimulates an activated CD40 receptor. EMBO J. 17, 1700–09. 44. Kim KR, Yoshizaki T, Miyamori H, Hasegawa K, Horikawa T, Furukawa M, Harada S, Seiki M and Sato H. (2000). Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene. 19, 1764-71. 45. Kondo S, Wakisaka N, Schell MJ, Horikawa T, Sheen TS, Sato H, Furukawa M, Pagano JS and Yoshizaki T. (2005). Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int J Cancer. 115, 368-76. 46. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V and Raab-Traub N. (1998). Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci U S A. 95, 11963-8. 47. Leavitt J, Latter G, Lutomski L, Goldstein D and Burbeck S. (1986). Tropomyosin isoform switching in tumorigenic human fibroblasts. Mol Cell Biol. 6, 2721-6. 48. Liebowitz D, Mannick J, Takada K and Kieff E. (1992). Phenotypes of Epstein–Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells. J Virol. 66, 4612–4616. 49. Lin JJ, Hegmann TE and Lin JL. (1988). Differential localization of tropomyosin isoforms in cultured nonmuscle cells. J Cell Biol. 107, 563-72. 50. Lin JJ, Warren KS, Wamboldt DD, Wang T and Lin JL. (1997). Tropomyosin isoforms in nonmuscle cells. Int Rev Cytol. 170, 1-38. 51. Liu MT, Chen YR, Chen SC, Hu CY, Lin CS, Chang YT, Wang WB and Chen JY. (2004). Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene. 23, 2531-9. 52. Liu LT, Peng JP, Chang HC, and Hung WC. (2003). RECK is a target of Epstein-Barr virus latent membrane protein 1. Oncogene. 22, 8263-70. 53. Ljungdahl S, Linder S, Franzen B, Binetruy B, Auer G and Shoshan MC. (1998). Down-regulation of tropomyosin-2 expression in c-Jun-transformed rat fibroblasts involves induction of a MEK1-dependent autocrine loop. Cell Growth Differ. 9, 565-73. 54. Lo AK, Liu Y, Wang XH, Huang DP, Yuen PW, Wong YC and Tsao GS. (2003). Alterations of biologic properties and gene expression in nasopharyngeal epithelial cells by the Epstein-Barr virus-encoded latent membrane protein 1. Lab Invest. 83, 697-709. 55. Lou P, Chen W, Sheen T, Ko J, Hsu M and Wu J. (1999). Expression of E-cadherin/catenin complex in nasopharyngeal carcinoma: correlation with clinicopathological parameters. Oncol Rep. 6, 1065-71. 56. Lu J, Chua HH, Chen SY, Chen JY and Tsai CH. (2003). Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res. 63, 256-62. 57. Lu JJ, JY Chen, Hsu TY, Yu WC, Su IJ and Yang CS. (1996). Induction of apoptosis in epithelial cells by Epstein-Barr virus latent membrane protein 1. J Gen Virol. 77, 1883-92. 58. Luka J, Kallin B and Klein G. (1979). Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94, 228-31. 59. Mahadev K, Raval G, Bharadwaj S, Willingham MC, Lange EM, Vonderhaar B, Salomon D and Prasad GL. (2002). Suppression of the transformed phenotype of breast cancer by tropomyosin-1. Exp Cell Res. 279, 40-51. 60. Mareel M, Boterberg T, Noe V, Van Hoorde L, Vermeulen S, Bruyneel E, and Bracke M. (1997). E-cadherin/catenin/cytoskeleton complex: a regulator of cancer invasion. J Cell Physiol. 173, 271-4. 61. Matsumura F, Lin JJ, Yamashiro-Matsumura S, Thomas GP and Topp WC. (1983). Differential expression of tropomyosin forms in the microfilaments isolated from normal and transformed rat cultured cells. J Biol Chem. 258, 13954-64. 62. Middeldorp JM, Brink AA, van den Brule AJ and Meijer CJ. (2003). Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol. 45, 1-36. 63. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D’Amico D, Bodner S, Oie H. K, Linnoila RI, Mulshine JL, Minna JD and Grazdar, A. F. (1992). p53 gene mutation in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutation and clinical features. Oncogene 7, 171-80. 64. Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M and Pagano JS. (2001) Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci U S A. 98, 6905-10. 65. Nawrocki-Raby B, Gilles C, Polette M, Martinella-Catusse C, Bonnet N, Puchelle E, Foidart JM, Van Roy F and Birembaut P. (2003). E-Cadherin mediates MMP down-regulation in highly invasive bronchial tumor cells. Am J Pathol. 163, 653-61. 66. Old DL, Boyse EA, Oettgen HF, de Harven E, Geering G, Williamson B and Clifford P. (1966). Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proc Natl Acad Sci USA 56, 1699-704. 67. Ono S and Ono K. (2002). Tropomyosin inhibits ADF/cofilin-dependent actin filament dynamics. Cell Biol. 156, 1065-76. 68. Pathmanathan R, Prasad U, Sadler R, Flynn K and Raab-Traub N. (1995). Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. New Engl J Med. 333, 693-8. 69. Pawlak G and Helfman DM. (2001). Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev. 11, 41-7. 70. Pawlak G, McGarvey TW, Nguyen TB, Tomaszewski JE, Puthiyaveettil R, Malkowicz SB and Helfman DM. (2004). Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder. Int J Cancer. 110, 368-73. 71. Pickard A, Chen CJ, Diehl SR, Liu MY, Cheng YJ, Hsu WL, Sun B, Hsu MM, Chen IH, Chen JY, Yang CS, Mittl BL, Chou SP, Ruggles DD, Goldstein AM and Hildesheim A. (2004). Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer. 111, 117-23. 72. Pollard TD and Borisy GG. (2003). Cellular motility driven by assembly and disassembly of actin filaments. Cell 112, 453–65. 73. Prasad GL, Fuldner RA and Cooper HL. (1993). Expression of transduced tropomyosin 1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene. Proc Natl Acad Sci U S A. 90, 7039-43. 74. Prasad GL, Masuelli L, Raj MH and Harindranath N. (1999). Suppression of src-induced transformed phenotype by expression of tropomyosin-1. Oncogene. 18, 2027-31. 75. Prasad GL, Meissner S, Sheer DG and Cooper HL. (1991). A cDNA encoding a muscle-type tropomyosin cloned from a human epithelial cell line: identity with human fibroblast tropomyosin TM1. Biochem Biophys Res Commun. 177, 1068-75. 76. Raval GN, Bharadwaj S, Levine EA, Willingham MC, Geary RL, Kute T and Prasad GL. (2003). Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene. 22, 6194-203. 77. Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu MR, O'neill GM, Yang N, Verrills NM, Kavallaris M and Gunning PW. (2005). Tissue-specific tropomyosin isoform composition. J Histochem Cytochem. 53, 557-70. 78. Shah V, Braverman R and Prasad GL. (1998). Suppression of neoplastic transformation and regulation of cytoskeleton by tropomyosins. Somat Cell Mol Genet. 24, 273-80. 79. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS and Wu CW. (2005). Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia. 7, 1058-64. 80. Shields JM, Mehta H, Pruitt K and Der CJ. (2002). Opposing roles of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in Ras-mediated downregulation of tropomyosin. Mol Cell Biol. 2304-17. 81. Skare J and Strominger JL. (1980). Cloning and mapping of BamHi endonuclease fragments of DNA from the transforming B95-8 strain of Epstein-Barr virus. Proc Natl Acad Sci USA. 77, 3860-64. 82. Suske G. (1999). The Sp-family of transcription factors. Gene. 238, 291-300. 83. Takenaga K and Masuda A. (1994). Restoration of microfilament bundle organization in v-raf-transformed NRK cells after transduction with tropomyosin 2 cDNA. Cancer Lett. 87, 47-53. 84. Takenaga K, Nakamura Y and Sakiyama S. (1988a). Differential expression of a tropomyosin isoform in low- and high-metastatic Lewis lung carcinoma cells. Mol Cell Biol. 8, 3934-7. 85. Takenaga K, Nakamura Y and Sakiyama S. (1988b). Suppression of synthesis of tropomyosin isoform 2 in metastatic v-Ha-ras-transformed NIH3T3 cells. Biochem Biophys Res Commun. 157, 1111-6. 86. Temm-Grove CJ, Jockusch BM, Weinberger RP, Schevzov G and Helfman DM. (1998). Distinct localizations of tropomyosin isoforms in LLC-PK1 epithelial cells suggests specialized function at cell-cell adhesions. Cell Motil Cytoskeleton. 40, 393-407. 87. Tsai CN, Tsai CL, Tse KP, Chang HY and Chang YS. (2002). The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A. 99, 10084-9. 88. Tsao SW, Tramoutanis G, Dawson CW, Lo AK and Huang DP. (2003). The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol. 12, 473-87. 89. Tovey MG, Lenoir G and Begon-Lours J. (1978). Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 276, 270-272. 90. Varga AE, Stourman NV, Zheng Q, Safina AF, Quan L, Li X, Sossey-Alaoui K and Bakin AV. (2005). Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta. Oncogene. 24, 5043-52. 91. Wakisaka N and Pagano JS. (2003). Epstein-Barr virus induces invasion and metastasis factors. Anticancer Res. 23, 2133-8. 92. Wang D, Liebowitz D and Kieff E. (1985). An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43, 831-40. 93. Wang FL, Wang Y, Wong WK, Liu Y, Addivinola FJ, Liang P, Chen LB, Kantoff PW and Pardee AB. (1996). Two differentially expressed genes in normal human prostate tissue and in carcinoma. Cancer Res. 56, 3634-7. 94. Weinberger R, Schevzov G, Jeffrey P, Gordon K, Hill M and Gunning P. (1996). The molecular composition of neuronal microfilaments is spatially and temporally regulated. J Neurosci. 16, 238-52. 95. Wilson JB, Weinberg W, Johnson R, Yuspa S and Levine AJ. (1990). Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell. 61, 1315-27. 96. Yokoyama Y, Kuramitsu Y, Takashima M, Iizuka N, Toda T, Terai S, Sakaida I, Oka M, Nakamura K and Okita K. (2004). Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics. 4, 2111-6. 97. Yoshizaki T, Sato H, Furukawa M, and Pagano JS. (1998). The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci U S A. 95, 3621-6. 98. Yoshizaki T, Horikawa T, Qing-Chun R, Wakisaka N, Takeshita H, Sheen TS, Lee SY, Sato H and Furukawa M. (2001). Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res. 7, 1946-51. 99. Young L, Alfieri C, Hennessy K, Evans H, O’Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E and Cohen J. (1989). Expression of Epstein-Barr virus transformation-association genes in tissue of patients with EBV lymphoproliferative disease. N Engl J Med. 321, 1080-5. 100. Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, Wang YB, Jiang MK, Fang Z and Meng NN. (1985). Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus Iga/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer. 36, 545–7. 101. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P and Santesson L. (1970). EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228, 1056-8. 102. zur Hausen H, O’Neill FJ, Freese UK, and Hecker E. (1978) Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature 272, 373-5. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/33815 | - |
| dc.description.abstract | 旋轉肌球素( Tropomyosin )是一種會與肌動蛋白結合( actin – binding )的蛋白質，具有穩定肌動蛋白絲( actin filament )的功能，過去研究發現，高分子量旋轉肌球素( HMW tropomyosin )的減少，可能與癌細胞轉移有關。高分子量旋轉肌球素是由TPM1及TPM2基因所產生，根據先前DNA微陣列晶片分析結果發現，表現EB病毒第一型潛伏膜蛋白( LMP1 )的細胞株中，TPM1 mRNA有減少的情況，先前研究已知LMP1會促進細胞侵襲能力，因此本研究欲進一步探討LMP1是否會藉由抑制TPM1- encoded 高分子量旋轉肌球素的產生，促進細胞的侵襲能力。
實驗結果發現，不管是利用短暫轉染( transient transfection )或者穩定表現LMP1的細胞株，與控制組比較，都有TPM1 mRNA及高分子量旋轉肌球素表現量減少的現象，而藉由啟動子活性試驗發現，LMP1的CTAR1和CTAR2兩個區域，對於LMP1抑制TPM1啟動子活性是必須的。將表現TPM1高分子量旋轉肌球素( TPM1-encoded HMW tropomyosins )的質體送入LMP1表現的細胞株，可以減少細胞侵襲能力。此外，將LMP1短暫轉染進入載體控制組及會表現TPM1的高分子量旋轉肌球素( TPM1- encoded HMW tropomyosins )的細胞株，發現載體控制組細胞侵襲能力增加約1.8倍，而表現高分子量旋轉肌球素的細胞株僅增加1.2倍左右。此結果顯示高分子量旋轉肌球素的減少，可能是LMP1促進細胞侵襲能力的諸多因素之一。至於LMP1透過那個訊息傳遞路徑減少TPM1的高分子量旋轉肌球素的產生，以及高分子量旋轉肌球素的減少造成促進細胞侵襲能力的機制，則需要進一步的實驗證明。 | zh_TW |
| dc.description.abstract | Tropomyosins are a family of actin-binding proteins that stabilize actin microfilament. High-molecular-weight (HMW) tropomyosins are encoded by TPM1 and TPM2 genes. Reduced HMW tropomyosin levels have been suggested to be associated with metastatic potential in cancer cell lines. Early studies have shown that the Epstein-Barr virus latent membrane protein 1 (LMP1) is correlated with promotion of cell invasion. TPM1 mRNA was found to be down-regulated in LMP1-expressing cell line as compared with control by cDNA microarray. In this study, we investigated whether down-regulation of TPM1-encoded HMW tropomyosin by LMP1 could promote cell invasion.
We demonstrated that TPM1 mRNA level and HMW tropomyosins were suppressed in LMP1-expressing cell lines. LMP1 could repress TPM1 gene expression through inhibition of TPM1 promoter activity. CTAR1 and CTAR2 domains were essential for repression of TPM1 promoter activity by LMP1. Forced expression of TPM1-encoded HMW tropomyosins in LMP1-expressing cells reverted LMP1-induced cell invasion. Transient expression of LMP1 in vector control cells, cell invasive ability increased approximately 2-fold. However, invasive ability was only up-regulated to 1.2-fold by LMP1 in TPM1-encoded HMW tropomyosin-expressing cells. These results suggested that LMP1 could down-regulate TPM1-encoded HMW tropomyosin, and reduction of HMW tropomyosin levels was associated with promotion of cell invasion. The mechanisms of repression of TPM1-encoded HMW tropomyosins by LMP1 and inhibition of cell invasion by HMW tropomyosins require further investigation. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T05:46:41Z (GMT). No. of bitstreams: 1 ntu-95-R93445115-1.pdf: 2651875 bytes, checksum: 6b2b9063322b218b7065734a95f7e375 (MD5) Previous issue date: 2006 | en |
| dc.description.tableofcontents | 中文摘要………………………………………………………………....1
英文摘要…………………………………………………………………2 1. 研究背景………………………………………………………….....3 1.1 EB病毒…………………………………………………………......................3 1.2 EB病毒之第一型潛伏膜蛋白…………………………………......................6 1.3 旋轉肌球素……………………………………………....................................9 2. 研究目的…………………………………………………………….13 3. 材料與方法………………………………………………………….14 3.1 材料……………………………………………………………......................14 3.2 方法……………………………………………………………......................18 4. 實驗結果…………………………………………………………….22 4.1 LMP1抑制TPM1 mRNA表現量…………………………….......................22 4.2 LMP1抑制TPM1所產生的高分子量旋轉肌球素表現量…………………22 4.3 LMP1抑制TPM1啟動子( promoter )的活性………………………………23 4.4 LMP1透過CTAR1及CTAR2區域抑制TPM1啟動子活性.......................24 4.5 增加細胞內TPM1-encoded高分子量旋轉肌球素可以減少LMP1所造成的細胞侵襲性…………………………………………………………………..24 4.6 大量表現TPM1-encoded高分子量旋轉肌球素之細胞株抵抗(resist) LMP1所引起的細胞侵襲性………………………………………………………..25 4.7 比較鼻咽癌及其他頭頸部癌症患部組織之高分子量旋轉肌球素表現量..26 5. 討論………………………………………………………………….28 5.1 LMP1影響高分子量旋轉肌球素表現量…………………………………...28 5.2 大量表現TPM1-encoded高分子量旋轉肌球素可以減少細胞侵襲能力...30 5.3 高分子量旋轉肌球素造成細胞侵襲能力減少的可能因素………………..32 5.4 未來工作……………………………………………………………………..33 6. 圖表………………………………………………………………….35 參考文獻……………………………………………………..................47 附錄…………………………………………………………..................57 | |
| dc.language.iso | zh-TW | |
| dc.subject | 第一型潛伏膜蛋白 | zh_TW |
| dc.subject | 旋轉肌球素 | zh_TW |
| dc.subject | 肌動蛋白絲 | zh_TW |
| dc.subject | 細胞侵襲性 | zh_TW |
| dc.subject | cell invasion | en |
| dc.subject | latent membrane protein 1 | en |
| dc.subject | tropomyosin | en |
| dc.subject | actin filament | en |
| dc.title | EB病毒第一型潛伏膜蛋白抑制旋轉肌球素1可促進人類上皮細胞的侵襲能力 | zh_TW |
| dc.title | Repression of TPM1 by EBV latent membrane protein 1 contributes to the invasiveness of human epithelial cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 94-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 王萬波 教授,李財坤 助理教授,夏興國 助理教授 | |
| dc.subject.keyword | 旋轉肌球素,第一型潛伏膜蛋白,細胞侵襲性,肌動蛋白絲, | zh_TW |
| dc.subject.keyword | tropomyosin,latent membrane protein 1,cell invasion,actin filament, | en |
| dc.relation.page | 58 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2006-07-12 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-95-1.pdf 未授權公開取用 | 2.59 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。